Literature DB >> 24276219

Adenylyl cyclase regulation in heart failure due to myocardial infarction in rats.

Jörg H Bräunig1, Barbara Albrecht-Küpper, Roland Seifert.   

Abstract

Cardiac adenylyl cyclase (AC) activity was described to be differentially regulated in left and right ventricles (LVs and RVs) of rats with heart failure (HF) due to LV myocardial infarction (MI) (Sethi et al. Am J Physiol 272:H884-H893, 1997). AC activities in LVs and RVs were increased and decreased respectively in rats 8 and 16 weeks post MI under basal and stimulatory conditions including AC activation via β-adrenergic receptors (β-ARs), stimulatory G protein (Gs), and direct AC activation with forskolin (FS). The current study aimed to detect alterations in rat heart AC activities in a comparable model of HF 9 weeks post LV MI. Therefore, cardiac AC activities were measured under basal and β-AR-, Gs-, or FS-stimulated conditions as well as under inhibition with various MANT [2'(3')-O-(N-methylanthraniloyl)]-nucleotide AC inhibitors and the P-site AC inhibitors NKY80 [2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone] and vidarabine (9-β-D-arabinosyladenine, AraAde). Basal and stimulated AC activities along with AC inhibition experiments did not reveal evidence for changes in AC activity in LVs and RVs from MI group animals despite the presence of congestive HF. However, our study is indeterminate. Further studies are required to identify the factors responsible for previously described changes in cardiac AC activity in MI induced HF and to elucidate the role of altered AC regulation in the pathophysiology of HF. In order to detect small changes in AC regulation, larger group sizes than the ones used in our present study are required.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24276219     DOI: 10.1007/s00210-013-0943-3

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  42 in total

Review 1.  Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase.

Authors:  N Defer; M Best-Belpomme; J Hanoune
Journal:  Am J Physiol Renal Physiol       Date:  2000-09

2.  Adenylyl cyclase and G protein receptor kinase expression during development of heart failure.

Authors:  P Ping; T Anzai; M Gao; H K Hammond
Journal:  Am J Physiol       Date:  1997-08

3.  Myocyte response to beta-adrenergic stimulation is preserved in the noninfarcted myocardium of globally dysfunctional rat hearts after myocardial infarction.

Authors:  A J Prahash; S Gupta; I S Anand
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

Review 4.  Changes in the receptor-G protein-adenylyl cyclase system in heart failure from various types of heart muscle disease.

Authors:  M R Bristow; A M Feldman
Journal:  Basic Res Cardiol       Date:  1992       Impact factor: 17.165

5.  Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases.

Authors:  Cibele Pinto; Gerald H Lushington; Mark Richter; Andreas Gille; Jens Geduhn; Burkhard König; Tung-Chung Mou; Stephen R Sprang; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2011-05-18       Impact factor: 5.858

6.  Isoform selectivity of adenylyl cyclase inhibitors: characterization of known and novel compounds.

Authors:  Cameron S Brand; Harrison J Hocker; Alemayehu A Gorfe; Claudio N Cavasotto; Carmen W Dessauer
Journal:  J Pharmacol Exp Ther       Date:  2013-09-04       Impact factor: 4.030

7.  Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase.

Authors:  Kosaku Iwatsubo; Claudio Bravo; Masami Uechi; Erdene Baljinnyam; Takashi Nakamura; Masanari Umemura; Lo Lai; Shumin Gao; Lin Yan; Xin Zhao; Misun Park; Hongyu Qiu; Satoshi Okumura; Mizuka Iwatsubo; Dorothy E Vatner; Stephen F Vatner; Yoshihiro Ishikawa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-13       Impact factor: 4.733

Review 8.  Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5.

Authors:  David Ho; Lin Yan; Kousaku Iwatsubo; Dorothy E Vatner; Stephen F Vatner
Journal:  Heart Fail Rev       Date:  2010-09       Impact factor: 4.214

9.  Broad specificity of mammalian adenylyl cyclase for interaction with 2',3'-substituted purine- and pyrimidine nucleotide inhibitors.

Authors:  Tung-Chung Mou; Andreas Gille; Srividya Suryanarayana; Mark Richter; Roland Seifert; Stephen R Sprang
Journal:  Mol Pharmacol       Date:  2006-06-09       Impact factor: 4.436

Review 10.  Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies.

Authors:  Rachna Sadana; Carmen W Dessauer
Journal:  Neurosignals       Date:  2008-10-24
View more
  4 in total

1.  Different degree of heart failure.

Authors:  Harvey Motulsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-04-22       Impact factor: 3.000

2.  Naunyn-Schmiedeberg's Archives of Pharmacology under new editorship: change and continuity.

Authors:  Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-24       Impact factor: 3.000

Review 3.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

4.  Chemical-induced cardiac reprogramming in vivo.

Authors:  Chenwen Huang; Wanzhi Tu; Yanbin Fu; Jinxi Wang; Xin Xie
Journal:  Cell Res       Date:  2018-04-18       Impact factor: 25.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.